Most Recent
A groundbreaking judgment by the Full Federal Court over competing class actions will be handed down Tuesday morning and is expected to give judges much needed guidance on how to move forward when confronted, as they increasingly are, with multiple proceedings over the same alleged misconduct.
Rebel Wilson has lost a bid to have the High Court reconsider an appeals court's decision to slash her record $4.75 million award in a defamation case against Bauer Media to $600,000.
A judge has adjourned an application by law firm Slater & Gordon for a common fund order in a class action against the Commonwealth Bank and its wealth management unit, amid two landmark challenges to the courts' powers to make such orders.
Two far-reaching appeals challenging the court's power to order all members of an open class action to pay a litigation funder will be heard together, and soon, the Federal Court's top judge said Thursday.
An appeals court has rejected the funder's commission and legal fees stemming from a $64 million settlement in litigation over the failure of Banksia Securities, but granted approval to the settlement.
A group representing patent and trade mark lawyers is seeking to intervene in a high-stakes appeal over computer software patents.
US seafood giant Trident Seafoods has filed an appeal over a trade mark registration by Australian rival Trident Foods, which will be heard by the Full Federal Court.
Scenic Tours has won a major victory on appeal in a class action against a ruling that put it on the hook for claims that luxury European river cruise passengers were owed damages and compensation after they were forced to take the bus because of flood waters.
H.J. Heinz Company has dropped its appeal of a ruling that it marketed its sugary snacks to kids as healthy, after the ACCC won a fraction of the $10 million fine it sought for the consumer law violations.
The High Court has dismissed the ACCC's bid to appeal a Full Federal Court decision upholding a ruling that drug giant Pfizer did not misuse its market power in the months leading up to the expiration of the patent for its blockbuster cholesterol drug Lipitor.